<DOC>
	<DOCNO>NCT01567540</DOCNO>
	<brief_summary>Hepatitis C infection major public health problem nearly 175 million infected individual worldwide . Although cure possible , 20-40 % patient spontaneously resolve infection 40-80 % chronically infected patient ( number vary depend viral genotype ) receive pegylated-interferon-alfa2a/ribavirin therapy clear virus sustain virologic responder ( SVR ) . Still many , virus manages circumvent natural immunity current therapeutic strategy , result significant morbidity mortality . To good define distinct clinical outcome HCV infection many investigator perform candidate molecule screen transcriptional profile order identify correlate viral clearance . One molecule gain significant attention CXCL10 ( also know interferon-gamma induced protein-10 IP-10 ) important negative prognostic biomarker . Given CXCL10 produce hepatocytes mediate chemo-attraction activated lymphocytes express CXCL10-receptor , CXCR3 , counter-intuitive chemokine correlate therapeutic non-responsiveness . The investigator hypothesize demonstrated CXCL10 cleave situ , result generation antagonist form chemokine . Based use specific inhibitor , investigator propose test whether protection agonist form CXCL10 increase responsiveness peg-IFN-alfa2 / ribavirin therapy . This achieve use DPPIV inhibitor , target enzyme responsible N-terminal truncation CXCL10 . If safety confirm , efficacy DPPIV-inhibition HCV patient test future trial examine potential clearance benefit .</brief_summary>
	<brief_title>A Pilot Study Evaluating Safety Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin Chronic Hepatitis C Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Age 18 70 year For woman , effective contraception trial negative pregnancy test ( urine ) enrollment Patients na√Øve prior hepatitis C treatment Confirmed HCV infection , base presence HCV antibodies plasma viremia allow measure circulate viral load Infection HCV genotype 1 4 Intent treatment Alfa2 pegylated IFN/ ribavirin HBV Infection HIV Infection Severe anemia ( Hb &lt; 78 g / dl ) Renal failure ( creatinine clearance &lt; 60 ml / min ) Taking digoxin within 6 month start treatment . Taking immunosuppressant within 6 month start treatment History serious hypersensitivity reaction ( anaphylactic shock angioedema ) sitagliptin Patients type I II diabetes Pregnancy absence effective contraception A person deprive liberty judicial administrative decision Living conditionssuggesting inability track schedule visit protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Interferon protein 10</keyword>
	<keyword>Chemokine gradient</keyword>
	<keyword>Sitagliptin</keyword>
</DOC>